NLM Digital Collections

Search

Start Over Authors Ollendorf, Daniel A., author ✖Remove constraint Authors: Ollendorf, Daniel A., author Authors Tice, Jeffrey A., author ✖Remove constraint Authors: Tice, Jeffrey A., author

1. The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection: a technology assessment : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, April 15, 2014
Subject(s):
Comparative Effectiveness Research
Hepatitis C, Chronic -- drug therapy
Heterocyclic Compounds, 3-Ring -- therapeutic use
Sulfonamides -- therapeutic use
Uridine Monophosphate -- analogs & derivatives
Uridine Monophosphate -- therapeutic use
Antiviral Agents -- economics
Antiviral Agents -- therapeutic use
Cost-Benefit Analysis
Drug Costs
Drug Therapy, Combination
Genotype
Hepatitis C -- economics
Hepatitis C -- genetics
Heterocyclic Compounds, 3-Ring -- adverse effects
Heterocyclic Compounds, 3-Ring -- economics
Insurance Coverage
Interferon-alpha -- therapeutic use
Oligopeptides -- therapeutic use
Polyethylene Glycols -- therapeutic use
Proline -- analogs & derivatives
Proline -- therapeutic use
Protease Inhibitors -- economics
Protease Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Ribavirin -- therapeutic use
Sulfonamides -- adverse effects
Technology Assessment, Biomedical
Treatment Outcome
Uridine Monophosphate -- adverse effects
Uridine Monophosphate -- economics
Value-Based Purchasing
Humans
United States

2. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Cunningham, Courtney, author
Pearson, Steven D., author
Kazi, Dhruv S., author
Coxson, Pamela G., author
Moran, Andrew E., author
Penko, Joanne, author
Guzman, David, author
Bibbins-Domingo, Kirsten, author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, November 24, 2015
Subject(s):
Anticholesteremic Agents -- therapeutic use
Azetidines -- therapeutic use
Enzyme Inhibitors -- therapeutic use
Hypercholesterolemia -- therapy
Hyperlipoproteinemia Type II -- prevention & control
Proprotein Convertases -- economics
Serine Endopeptidases -- economics
Cholesterol, LDL
Cost-Benefit Analysis
Decision Support Techniques
Drug Costs
Drug Resistance
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
Technology Assessment, Biomedical
Treatment Outcome
Value-Based Purchasing
Humans
New England
United States

3. Integrating behavioral health into primary care: a technology assessment : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Reed, Sarah Jane, author
Shore, Karen K., author
Weissberg, Jed, author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, June 2, 2015
Subject(s):
Delivery of Health Care, Integrated -- methods
Delivery of Health Care, Integrated -- organization & administration
Mental Health Services -- organization & administration
Outcome Assessment (Health Care) -- organization & administration
Primary Health Care -- organization & administration
Technology Assessment, Biomedical
Anxiety Disorders -- therapy
Chronic Disease
Clinical Competence
Confidentiality
Depression -- therapy
Electronic Health Records
Health Manpower
Health Status
Information Services
Insurance Coverage
Insurance, Health
Medicaid
Medicare
Models, Organizational
Patient Satisfaction
Practice Guidelines as Topic
Quality of Life
Reimbursement Mechanisms
Substance-Related Disorders -- therapy
Humans
United States

4. Mepolizumab (Nucala??, GlaxoSmithKline plc.) for the treatment of severe asthma with eosinophilia: effectiveness, value, and value-based price benchmarks : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Campbell, Jonathan D., author
Chapman, Rick, author
Shore, Karen K., author
Weissberg, Jed, author
Whittington, Melanie, author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, March 14, 2016
Subject(s):
Adrenergic beta-2 Receptor Agonists -- economics
Adrenergic beta-2 Receptor Agonists -- therapeutic use
Anti-Asthmatic Agents -- administration & dosage
Anti-Asthmatic Agents -- economics
Antibodies, Monoclonal, Humanized -- administration & dosage
Antibodies, Monoclonal, Humanized -- economics
Asthma -- drug therapy
Asthma -- immunology
Eosinophilia -- drug therapy
Interleukin-5 -- immunology
Cost-Benefit Analysis
Glucocorticoids -- administration & dosage
Humans
United States

5. Insulin degludec (Tresiba??, Novo Nordisk A/S) for the treatment of diabetes: effectiveness, value, and value-based price benchmarks : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Chapman, Rick, author
Shore, Karen K., author
Weissberg, Jed, author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, March 14, 2016
Subject(s):
Blood Glucose -- drug effects
Diabetes Mellitus, Type 1 -- drug therapy
Diabetes Mellitus, Type 2 -- drug therapy
Hypoglycemia -- prevention & control
Hypoglycemic Agents -- therapeutic use
Insulin, Long-Acting -- administration & dosage
Insulin, Long-Acting -- therapeutic use
Blood Glucose -- metabolism
Cost-Benefit Analysis
Diabetes Mellitus, Type 1 -- blood
Diabetes Mellitus, Type 1 -- complications
Diabetes Mellitus, Type 2 -- blood
Diabetes Mellitus, Type 2 -- complications
Hypoglycemia -- blood
Hypoglycemia -- chemically induced
Hypoglycemic Agents -- administration & dosage
Insulin -- adverse effects
Severity of Illness Index
Humans
United States

6. Controversies in migraine management: a technology assessment : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Weissberg, Jed, author
Shore, Karen K., author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, August 19, 2014
Subject(s):
Analgesics, Opioid -- therapeutic use
Botulinum Toxins, Type A -- therapeutic use
Emergency Medical Services
Magnetic Field Therapy
Migraine Disorders -- drug therapy
Migraine Disorders -- economics
Migraine Disorders -- prevention & control
Migraine Disorders -- therapy
Transcutaneous Electric Nerve Stimulation
Analgesics, Opioid -- adverse effects
Analgesics, Opioid -- economics
Chronic Disease
Cost-Benefit Analysis
Disease Management
Insurance Coverage
Migraine Disorders -- epidemiology
Migraine with Aura -- therapy
Randomized Controlled Trials as Topic
Technology Assessment, Biomedical
Treatment Outcome
Humans
California
United States

7. Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects: revised evidence report

Author(s):
Tice, Jeffrey A., author
McKenna, Avery, author
Herce-Hagiwara, Belén, author
Moradi, Ashton, author
Pearson, Steven D., author
Ollendorf, Daniel A., author
Bloudek, Lisa, author
Carlson, Josh J., author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, March 17, 2022
Subject(s):
Antineoplastic Agents -- adverse effects
Chemotherapy-Induced Febrile Neutropenia -- drug therapy
Chemotherapy-Induced Febrile Neutropenia -- prevention & control
Neutropenia -- drug therapy
Neutropenia -- prevention & control
United States